REVISITING THE SAFETY PROFILE OF TOPICAL CALCINEURIN INHIBITORS IN ATOPIC DERMATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2015–2026) IN THE CONTEXT OF PUBLIC HEALTH REGULATIONS
Authors:
- Anna ZłotnikAZAnna Złotnik
- Kinga KrzysztofikKKKinga Krzysztofik
- Antoni KlamkaAKAntoni Klamka
- Paulina KawalecPKPaulina Kawalec
- Kamil BronikowskiKBKamil Bronikowski
- Maksymilian RyszkowskiMRMaksymilian Ryszkowski
- Krystian FornalKFKrystian Fornal
- Natalia BęDkowska-KuśmierekNBNatalia BęDkowska-Kuśmierek
- Sabina ZaborowskaSZSabina Zaborowska
- Paulina PawlakPPPaulina Pawlak
Open Access
- 29 June 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Abstract
Background. Atopic Dermatitis (AD) is a widespread, chronic inflammatory-related skin con-dition. Despite the effectiveness of topical calcineurin inhibitors (TCIs), their use is often limited by "TCI phobia" fueled by FDA "black box" warnings regarding potential oncological risks. These warnings were based on animal model studies conducted early in the development of the drug and systemic transplantation data. Aim. The aim of this study is to evaluate the oncological safety of TCIs in patients with atopic dermatitis by synthesizing the latest epidemiological evidence (2015–2026) and to discuss the implications of current public health regulator restrictions. Material and methods. A systematic review and meta-analysis adhered to the PRISMA 2020 guidelines. Databases (PubMed, Embase) were searched for cohort and case-control studies. Ten high-quality studies (Newcastle-Ottawa Scale ≥7) were selected. Statistical analysis was performed using JASP (Version 0.18.3) with a random-effects model (Restricted ML) to calcu-late pooled Relative Risks (RR) and evaluate heterogeneity (I2). Results. The quantitative synthesis included diverse age and geographical cohorts. The analysis revealed that TCI use is not associated with a statistically significant increase in the overall risk of malignancy (pooled RR = 0.97; 95% CI: 0.82–1.15; p = 0.529). Heterogeneity was non-existent (I2 = 0%). Long-term data (e.g., APPLES study) and large-scale pharmacovigilance reports (17 million FAERS records) confirmed no increased risk of lymphomas or hematopoietic malignancies. Conclusions. The oncological safety profile of TCIs is favorable and supported by pharmaco-kinetic evidence, that shows minor systemic absorption (< 1.0 ng/mL). Systemic cancer cases associated with TCI(s) are most likely historically attributed to protopathic bias. These findings strongly supports the removal of the "black box" warnings to reduce "TCI phobia" and improve therapeutic outcomes and quality of life for AD patients.Keywords
This publication has 17 references indexed in Scilit:
- Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025)JAAD International, 2026
- LB908 Risk of cutaneous squamous cell carcinoma following topical calcineurin inhibitor use: a retrospective cohort analysisJournal of Investigative Dermatology, 2024
- Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysisThe Lancet Child & Adolescent Health, 2022
- Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic DermatitisJAMA Dermatology, 2020
- No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitisJournal of the American Academy of Dermatology, 2020
- Association Between Malignancy and Topical Use of PimecrolimusJAMA Dermatology, 2015
- Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infantsPediatric Allergy and Immunology, 2015
- Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequencyBritish Journal of Dermatology, 2011
- Farmacocinética del tacrolimus tras la aplicación tópica de una pomada de tacrolimus en pacientes adultos y pediátricos con dermatitis atópicaActas Dermo-Sifiliograficas, 2008
- Pimecrolimus – an anti‐inflammatory drug targeting the skinExperimental Dermatology, 2004